Irish journal of medical science · 2026
Subclinical inflammation and early pathogenesis of rheumatic diseases: mechanistic insights relevant to primary care.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Wentong, Liu Yajing, Wang Xiaodong, Liu Jinxin, Su Yuhua
Аннотация
Rheumatic diseases exhibit insidious onset and non-specific early manifestations, causing substantial diagnostic delays in primary care. This delay is closely linked to a prolonged subclinical inflammation phase, where pathogenic immune processes are active yet clinically inapparent. The mechanistic basis of this early disease concealment remains incompletely synthesized. Subclinical inflammation represents a state of persistent, low-grade immune activation in the absence of overt clinical signs, structural damage, or marked laboratory abnormalities. This phase is driven primarily by innate immune priming, sterile inflammation, and low-intensity cytokine signaling, which together sustain immune dysregulation below conventional diagnostic thresholds. Key processes include pattern recognition receptor activation, inflammasome signaling, modest but chronic cytokine production, and gradual erosion of immune tolerance. These mechanisms precede adaptive immune engagement, autoantibody maturation, and tissue-specific inflammation, thereby creating a temporal dissociation between molecular pathology and clinical expression. Disease-specific evidence from rheumatoid arthritis and systemic lupus erythematosus how subclinical inflammation constitutes a common early pathogenic state across diverse rheumatic conditions. Importantly, the heterogeneity and compartmentalization of early immune activation explain why routine clinical assessment and standard inflammatory markers frequently fail to detect active disease in primary care. By integrating current mechanistic insights, this review reframes diagnostic delay as a biologically driven phenomenon rather than a limitation of clinical practice. Understanding the mechanisms of subclinical inflammation provides a rational framework for risk-informed recognition and timely referral in primary care, with potential implications for improving long-term outcomes in rheumatic diseases.